ELEVECTA™ transient cell line

For viral vector production.

Variant

ELEVECTA™ transient cell line

To buy, choose your product.

Price includes standard shipping and handling

Overview

The ELEVECTA™ transient cell line is a flexible option for producing viral vectors using triple transfection. It’s designed to minimize development time and quickly advance promising candidates to clinical trials.

High performance: achieve high titers of infectious virus, with further gains enabled by process enhancers.
Enhanced product quality: reduce encapsidated host cell DNA.
Regulatory advantage: granted FDA Advanced Manufacturing Technology (AMT) designation, enabling earlier, more structured FDA engagement and reducing regulatory uncertainty from development through clinical manufacturing.
Future-ready: leverage ongoing advances in cell line engineering to support seamless transitions as your needs evolve.
Collaborative support: partner beyond supply with a comprehensive suite of regulatory and technical services to accelerate clinical progress.

Contact us at ELEVECTA@cytiva.com to speak directly to our specialists.